X @The Wall Street Journal
The Wall Street Journal·2025-12-10 14:23
Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, according to the company. https://t.co/XhER14Hk2T ...
Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, according to the company. https://t.co/XhER14Hk2T ...